People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Coeptis Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $19.5M | $16.4M | 2018 |
| Coeptis Therapeutics Holdings, Inc. | — | Pharmaceuticals | Series A | $10.3M | $12.8M | 2023 |
| Coeptis Therapeutics Inc. | — | Pharmaceuticals | Series A | $5.5M | $125.1M | 2021 |
| Jabez Biosciences, Inc. | — | Biotechnology | Seed | $1.6M | $991K | 2024 |
| Nok Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $817K | $976K | 2024 |
David Mehalick at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Mehalick on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.